By entering this site, you are confirming that you are a healthcare professional within your selected country.
Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email to aereporting@jazzpharma.com or by fax to +44(0) 1865 598765
This link has been provided for you to access Jazz Pharmaceuticals terms and conditions only; it does not constitute an endorsement or promotion of any product
This link has been provided for you to access the Jazz Pharmaceuticals privacy statement only; it does not constitute an endorsement or promotion of any product
You are now being directed to the Knowledge Network Members Area, where access is restricted to members only
Healthcare professionals are asked to report any suspected adverse events via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email to aereporting@jazzpharma.com or by fax to +44(0) 1865 598765
REMINDER: The Nurses Learning Centre courses for UK and Spain will be hosted externally. Navigation to these will be available on the previous page once they are available.
This page contains promotional information on Defitelio (defibrotide) and has been developed in-line with EU marketing authorisation. Please consult local prescribing information for further information.